Navigation Links
UT Southwestern researchers find gene mutation that leads to 'broken hearts'

Researchers at UT Southwestern Medical Center have identified a group of fruit fly gene mutations responsible for "broken hearts" in the embryonic stages of development, a discovery that could help identify genes that cause human heart defects.

"We engineered a fruit fly so that the heart would glow in the dark and found a new type of malformation, completely unexpectedly," said Dr. Eric Olson, chairman of molecular biology at UT Southwestern and senior author of the study appearing in today's issue of Science. "We coined the term 'brokenhearted' for this defect because two kinds of cardiac cells separated, thus causing the heart to fall apart, with a loss of heart function and embryonic death."

The heart is the first organ to form and function in the embryo. Abnormalities in the complex process of heart formation result in congenital heart defects, the most common birth defects in humans afflicting about 1 percent of newborns. Because the events of heart formation are very similar throughout the animal world, the fruit fly is a useful model to study the causes of heart defects in mammals, Dr. Olson said.

The researchers found that mutations in genes encoding enzymes in a pathway for synthesis of a small lipid caused this broken heart defect in fruit flies. One of these enzymes, HMG CoA reductase, also plays a key role in the synthesis of cholesterol in humans. In fruit flies, these enzymes are required to generate a small lipid to modify a signaling protein, which is required for heart formation. The study suggests the involvement of the same biochemical pathway in human heart formation and congenital heart disease.

"We were surprised to discover that a group of enzymes involved in lipid synthesis plays a previously unrecognized role in assembling the heart. The same mechanism is likely to be involved in human-heart development," said Dr. Olson, director of the Nancy B. and Jake L. Hamon Center for Basic Research in Canc
'"/>

Source:UT Southwestern Medical Center


Page: 1 2

Related biology news :

1. UT Southwestern researchers discover master switch in cell death
2. UT Southwestern researchers develop screening test for cells that activate immune system
3. UT Southwestern researchers unravel control of growing blood vessels
4. DNA end caps may lead to cancer treatments, UT Southwestern researchers report
5. Napoleons mysterious death unmasked, UT Southwestern researcher says
6. NYU researchers simulate molecular biological clock
7. Vital step in cellular migration described by UCSD medical researchers
8. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
9. UCSD researchers maintain stem cells without contaminated animal feeder layers
10. Why do insects stop breathing? To avoid damage from too much oxygen, say researchers
11. New protein discovered by Hebrew University researchers

Post Your Comments:
(Date:11/19/2009)...t Louisiana Tech University has found that a natur...bicide against giant salvinia. , Giant salvinia ...ock all sunlight penetration into bodies of water,...ns, it,s been reported that giant salvinia can dou...er, professor of biological sciences at Louisiana ...
(Date:11/19/2009)...s identified thousands of diverse genes in genetic...niques may allow breeders and researchers to use t... and create new varieties that were not easily pos...of Science , the researchers, whose senior and fi...st map of haplotypes sets of closely linked gene ...
(Date:11/19/2009)...hnique developed by researchers at the University ... specific gene-regulatory regions without requirin...ctors. The technique has been experimentally valid...nome. , "Our statistical approach is more widely ...y useful for investigating gene regulatory network...
Breaking Biology News(10 mins):Microorganism may provide key to combating giant salvinia throughout Louisiana 2New map of variation in maize genetics holds promise for developing new varieties 2Technique finds gene regulatory sites without knowledge of regulators 2Kaiser Permanente Debuts New Ads Focused on Technology and Innovation 55897 1Kaiser Permanente Debuts New Ads Focused on Technology and Innovation 55897 2Kaiser Permanente Debuts New Ads Focused on Technology and Innovation 55897 3Monsanto Licenses Use of Cellectis Innovative Genome Modification Technology 13776 1Monsanto Licenses Use of Cellectis Innovative Genome Modification Technology 13776 2Monsanto Licenses Use of Cellectis Innovative Genome Modification Technology 13776 3Drug Czar Launches Nationwide Meth Prevention Advertising 55890 1Drug Czar Launches Nationwide Meth Prevention Advertising 55890 2Drug Czar Launches Nationwide Meth Prevention Advertising 55890 3Drug Czar Launches Nationwide Meth Prevention Advertising 55890 4
...ith American researchers to pinpoint why only some...Associate Professor Peter Dodd and his team from U... secured a five-year, $1.23 million grant from the...al Institute of Health (NIH) to find out. , Chro...f the brain, which affect planning, and social int...
...e (NCI) and the National Human Genome Research Ins...es of Health (NIH), today launched a comprehensive...ecular basis of cancer through the application of ...le genome sequencing. The overall effort, called T...ilot project to determine the feasibility of a ful...
...t cause tooth decay to be able to live without som...tists have long believed a certain biochemical pat...ins to cell membranes is essential for survival. N...ed that Streptococcus mutans, the decay-causing or...ine without it. , The findings, reported this mon...
Other Biology News:Mapping alcohol brain damage 2NIH launches comprehensive effort to explore cancer genomics 2NIH launches comprehensive effort to explore cancer genomics 3NIH launches comprehensive effort to explore cancer genomics 4Bacteria that cause tooth decay able to survive without important biochemical pathway 2Bacteria that cause tooth decay able to survive without important biochemical pathway 3
(Date:11/20/2009)... have an opportunity to take the lead in two small...rsity of Valencia (UV), working together with the ...bric of the Spanish biotechnology industry. Their ...have more clout than those in English-speaking cou...lants has been overlooked by the leading countries...
(Date:11/20/2009)...ewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI...Ninth Circuit Court of Appeals reversed a U.S. Dis...owed to pursue all of its claims against The Lash ... for trial. CTI filed a complaint against The Las...nsultant for CTI,s product TRISENOX, in 2007 seeki...
(Date:11/19/2009)...ire-FirstCall/ -- Omeros Corporation (Nasdaq: OME...r the third quarter ended September 30, 2009. For ...reported a net loss of $3.9 million, or $1.34 per ...or $2.54 per share, for the same period in 2008. F...ompany reported a net loss of $15.5 million, or $5...
(Date:11/19/2009)...HAM, Mass., Nov. 19 Arlington Medi...at the leading driver of antibiotic selection in n...tivity against gram-positive and gram-negative pat...ause nosocomial pneumonia, surveyed European physi...hat provide appropriate coverage against common pa...
Breaking Biology Technology:Spanish biotechnology should focus on food and plant sectors to be more competitive 2Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3
...Call/ - Dragon Pharmaceutical Inc.,(TSX: DDD; OTCB...results,for the second quarter ended June 30, 2007...les increased 48% to $20.55 million from $13.89 mi...sed 19% as compared to the first quarter 2007... $3.98 million and 19.36% from $2.39 million ...
... XTL,Biopharmaceuticals Ltd. (NASDAQ: XTLB ; LSE:...ged in the acquisition, development and,commercial... medical needs,particularly neuropathic pain and h...for the six months ended June 30, 2007. At June 3...d short-term,bank deposits of $12.6 million, compa...
...peutics,Inc. (Nasdaq: CVTX ) announced today that... College of Cardiology Foundation and the American...sue of Circulation, state that,"ranolazine may be ...TEMI." Ranexa(R) (ranolazine extended-release tab...gina in patients who have not achieved an adequate...
Other Biology Technology:Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007 2Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007 3XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 2XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 3XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 4XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 5XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 6XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 7XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 8XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 9XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 10XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 11XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 12XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 13XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 14Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI) 2
Wellwash AC Big Bottles (100-240 V) from Thermo Scientific
Wellwash 4 Mk 2 from Thermo Scientific
File Holder from Terra Universal, Inc.
...he research-grade spectrofluorometer with a minimu...tio 200 or greater for the Raman band of water. ,T...in order to meet requirements in biochemistry as k...easurements. ,The FP-6500 is designed to keep GLP/...
Biology Products: